Skip to main content
Premium Trial:

Request an Annual Quote

New Journal in Town

A new scientific journal backed by venture capitalist Tim O'Reilly relies on a one-time fee for researchers to be able to publish articles there, reports Reuters. The journal, called PeerJ, is the brainchild of Peter Binfield — formerly of PLoS One — and Jason Hoyt — formerly at Mendeley — and it will focus on the biological and medical sciences. "We really flip the whole business model from one where the author pays for a publication to a membership model where they pay just once," Binfield tells ScienceInsider.

PeerJ currently offers three membership options: a basic plan that is $99 and allows researchers to publish one article a year, a $169 plan that allows two publications a year, and a $259 unlimited plan. The prices also vary depending on whether researchers are joining as they submit a paper to after a paper has been accepted. ScienceInsider notes that all authors will need to join.

"I have been waiting for things like this," says the University of California, Davis' Jonathan Eisen, an open-access advocate and the academic editor-in-chief of PLoS Biology, at ScienceInsider. "We need publishers who experiment."

PeerJ will be accepting submissions beginning at the end of the summer and will begin publishing at the end of the year.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.